4D Molecular Therapeutics, Inc. (FDMT)
10.46
-0.33
(-3.06%)
USD |
NASDAQ |
Nov 18, 16:00
10.46
0.00 (0.00%)
After-Hours: 20:00
4D Molecular Therapeutics Net Income (Quarterly) : -78.06M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -78.06M |
| June 30, 2026 | -72.94M |
| March 31, 2026 | -68.76M |
| December 31, 2025 | 19.40M |
| September 30, 2025 | -56.88M |
| June 30, 2025 | -54.66M |
| March 31, 2025 | -47.97M |
| December 31, 2024 | -49.67M |
| September 30, 2024 | -43.84M |
| June 30, 2024 | -34.95M |
| March 31, 2024 | -32.40M |
| September 30, 2023 | -10.26M |
| June 30, 2023 | -29.62M |
| March 31, 2023 | -28.68M |
| Date | Value |
|---|---|
| December 31, 2022 | -27.38M |
| September 30, 2022 | -25.69M |
| June 30, 2022 | -28.09M |
| March 31, 2022 | -26.34M |
| December 31, 2021 | -25.08M |
| September 30, 2021 | -22.24M |
| June 30, 2021 | -7.589M |
| March 31, 2021 | -16.41M |
| September 30, 2020 | -7.833M |
| June 30, 2020 | -15.15M |
| March 31, 2020 | -13.16M |
| December 31, 2019 | -16.12M |
| September 30, 2019 | -16.68M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | 1.567M |
| Amgen, Inc. | 3.864B |
| Anika Therapeutics, Inc. | -0.311M |
| BioCryst Pharmaceuticals, Inc. | 37.92M |
| Imunon, Inc. | -3.750M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 4.145M |
| Total Expenses (Quarterly) | 82.20M |
| EPS Diluted (Quarterly) | -1.080 |
| Enterprise Value | 321.10M |
| Gross Profit Margin (Quarterly) | 51.63% |
| Profit Margin (Quarterly) | -1.88K% |
| Earnings Yield | -26.69% |
| Normalized Earnings Yield | -26.69 |